Legal Issues and BPCI Act

 The legal problems regarding the follow-on-biologics associate degreed biosimilars are one of the foremost aspects that want an open discussion. Before the actual advent of biosimilars to the market legal problems have up in numbers in their biological process stages. Known organizations have filed cases against alternative 2 claims their rights and for other legal allegations related to the product. This track is dedicated to discussion of all such cases that has been argued among the court of law.

By 2002, the authority had approved thirty six new biologics, followed by thirty seven additional in 2003, another forty in 2004 and thirty-nine additional in 2005. By 2006, the leading class of biological treatment, the red corpuscle attention recombinant glycoprotein (EPO), generated $14 billion in sales revenues, or forty p.c quite the popular ancient pharmaceutical, Lipitor. quite three hundred therapeutic antibodies presently are in clinical development and trials, compared to solely thirteen that already are wide accessible because of legal problems.

    Related Conference of Legal Issues and BPCI Act

    November 27-27, 2021

    Drug Formulation Bioavailability 2021

    London, UK
    February 07-08, 2022

    World Congress on Pharmaceutical Chemistry

    Paris, France

    Legal Issues and BPCI Act Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in